BerandaLT3 • FRA
add
AxoGen, Inc Common Stock
Tutup sebelumnya
€10,30
Rentang hari
€10,30 - €10,60
Rentang tahun
€5,20 - €19,20
Kapitalisasi pasar
538,79 jt USD
Volume Rata-Rata
7,00
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Pendapatan | 48,56 jt | 17,36% |
Biaya operasional | 36,59 jt | -1,58% |
Laba bersih | -3,83 jt | 42,22% |
Margin laba bersih | -7,90 | 50,75% |
Penghasilan per saham | -0,02 | 66,67% |
EBITDA | 134,00 rb | 104,50% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
(USD) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 22,07 jt | 25,15% |
Total aset | 196,16 jt | 5,17% |
Total liabilitas | 90,80 jt | -2,74% |
Total ekuitas | 105,36 jt | — |
Saham yang beredar | 45,54 jt | — |
Harga terhadap nilai buku | 4,44 | — |
Tingkat pengembalian aset | -2,08% | — |
Tingkat pengembalian modal | -2,36% | — |
Arus Kas
Perubahan kas bersih
(USD) | Mar 2025info | Perubahan Y/Y |
---|---|---|
Laba bersih | -3,83 jt | 42,22% |
Kas dari operasi | -13,18 jt | -7,44% |
Kas dari investasi | 1,34 jt | 141,19% |
Kas dari pembiayaan | 2,38 jt | 1.067,65% |
Perubahan kas bersih | -9,46 jt | 38,24% |
Arus kas bebas | -12,34 jt | -9,71% |
Tentang
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Didirikan
2002
Kantor pusat
Situs
Karyawan
452